Abstract
Most patients with Crohn's disease will require surgery during the course of their disease. However, surgery is not curative and post-operative recurrence is quite inexorable. One year after resection up to 80% of patients have new lesions at the neo-terminal ileum and after 10 years approximately 50% of patients will experience recurrence of symptoms and 35% will need further surgery. Prevention of post-operative recurrence has, therefore, a central role in the management of Crohn's Disease. Several drugs have been evaluated to decrease the risk of both endoscopic and clinical recurrence but the overall results are largely not impressive. Among the different drugs evaluated, mesalazine, antibiotics (metronidazole and ornidazole), thiopurines and anti-TNFα antibodies have been shown to be effective whereas budesonide, probiotics and interleukin 10 are not effective. This review focuses on the actual evidence on the prevention of postoperative recurrence: randomised controlled trials and meta-analyses are critically reviewed and discussed with particular attention to the methodological aspects.
Keywords: Crohn's disease, post-operative recurrence, mesalazine, thiopurines, biologic therapies, antibiotics, probiotics, budesonide
Reviews on Recent Clinical Trials
Title:Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease
Volume: 7 Issue: 4
Author(s): Claudio Papi, Federica Fasci Spurio, Giovanna Margagnoni and Annalisa Aratari
Affiliation:
Keywords: Crohn's disease, post-operative recurrence, mesalazine, thiopurines, biologic therapies, antibiotics, probiotics, budesonide
Abstract: Most patients with Crohn's disease will require surgery during the course of their disease. However, surgery is not curative and post-operative recurrence is quite inexorable. One year after resection up to 80% of patients have new lesions at the neo-terminal ileum and after 10 years approximately 50% of patients will experience recurrence of symptoms and 35% will need further surgery. Prevention of post-operative recurrence has, therefore, a central role in the management of Crohn's Disease. Several drugs have been evaluated to decrease the risk of both endoscopic and clinical recurrence but the overall results are largely not impressive. Among the different drugs evaluated, mesalazine, antibiotics (metronidazole and ornidazole), thiopurines and anti-TNFα antibodies have been shown to be effective whereas budesonide, probiotics and interleukin 10 are not effective. This review focuses on the actual evidence on the prevention of postoperative recurrence: randomised controlled trials and meta-analyses are critically reviewed and discussed with particular attention to the methodological aspects.
Export Options
About this article
Cite this article as:
Papi Claudio, Fasci Spurio Federica, Margagnoni Giovanna and Aratari Annalisa, Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease, Reviews on Recent Clinical Trials 2012; 7 (4) . https://dx.doi.org/10.2174/1574887111207040307
DOI https://dx.doi.org/10.2174/1574887111207040307 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Seeking Novel Targets for Improving In Vivo Macrophage-Specific Reverse Cholesterol Transport: Translating Basic Science into New Therapies for the Prevention and Treatment of Atherosclerosis
Current Vascular Pharmacology Immunophilins and Cardiovascular Complications
Current Medicinal Chemistry Nutraceutical, Antioxidant, Antimicrobial Properties of <i>Pyropia vietnamensis</i> (Tanaka et Pham-Hong Ho) J.E. Sutherl. et Monotilla
Current Bioactive Compounds Phospholipase A2 Myotoxins from Bothrops Snake Venoms: Structure- Function Relationship
Current Organic Chemistry Development and Evaluation of Topical Nanoemulgel Formulation of Tazarotene for Effective Treatment of Excision Wounds
Current Nanomedicine Understanding Human Immunodeficiency Virus Type 1 and Hepatitis C Virus Coinfection
Current HIV Research Protein Kinase C Isoforms - Implications to Thrombosis
Current Signal Transduction Therapy Sleep Loss and Hypertension: A Systematic Review
Current Pharmaceutical Design The Potential Applications of Stem Cells for Cancer Treatment
Current Stem Cell Research & Therapy Cytochrome P450 Pharmacogenetics in Drug Development: In Vitro Studies and Clinical Consequences
Current Drug Metabolism Stem Cell Interventions for Bone Healing: Fractures and Osteoporosis
Current Stem Cell Research & Therapy Designed Multiple Ligands for Cancer Therapy
Current Medicinal Chemistry Was Phenserine a Failure or Were Investigators Mislead by Methods?
Current Alzheimer Research Monitoring Inflammation, Humoral and Cell-mediated Immunity in Pancreas and Islet Transplants
Current Diabetes Reviews Chronic Tendon Pain-Implications for Treatment: An Update
Current Drug Targets What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets Recent Advances on Detection of Modified Forms of Low-Density Lipoproteins
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Emerging In Vitro Tools to Evaluate Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions
Current Drug Discovery Technologies